VUMC researchers a step closer to broad ebolavirus protection

Diagnostic Laboratory Services set for relocation, expansion

Vanderbilt’s Diagnostic Laboratory Services are undergoing a major relocation and expansion project.

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

Molecular imaging of C. diff infection

C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

Caught in a web: study reveals that immune cells cooperate to trap and kill bacteria

Vanderbilt researchers have identified a new antibacterial mechanism that could inspire novel strategies for combating staph and other extracellular bacterial pathogens.